ARONORA, INC

Company Information
Address 4640 SW MACADAM AVE STE 200A
PORTLAND, OR, 97239-4232

http://www.aronorabio.com

Information

DUNS: 078698200

# of Employees: 8


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Therapeutic Protein C Activator for Myocardial Ischemia

    Amount: $998,107.00

    PROJECT SUMMARY Heart attack or acute myocardial infarction AMI is a leading cause of death in the United States with over victims every year The most prevalent cause of AMI is progressi ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. HLS- Factor XII Inhibitor for Surface Initiated Thrombosis

    Amount: $299,563.00

    DESCRIPTION provided by applicant This Phase I II Fast Track application is being re submitted under the NHLBI Small Business Topics of Special Interest for Fiscal Year HLS Certain lif ...

    SBIRPhase I2016Department of Health and Human Services
  3. Therapeutic factor XI blockade for sepsis

    Amount: $1,996,412.00

    DESCRIPTION provided by applicant Sepsis a detrimental systemic inflammatory and procoagulant response to infections remains a leading cause of death despite antibiotics and significant advances ...

    SBIRPhase II2015Department of Health and Human Services
  4. Therapeutic Thrombin Analogs

    Amount: $2,664,749.00

    DESCRIPTION (provided by applicant): Project Summary/Abstract Treatment of acute ischemic stroke (AIS) with the thrombolytic/antithrombotic agent tissue plasminogen activator (tPA, Activase(R)) is lim ...

    SBIRPhase II2014Department of Health and Human Services
  5. Therapeutic Thrombin Analogs

    Amount: $2,664,749.00

    DESCRIPTION provided by applicant Project Summary Abstract Treatment of acute ischemic stroke AIS with the thrombolytic antithrombotic agent tissue plasminogen activator tPA Activase is limit ...

    SBIRPhase II2014Department of Health and Human Services
  6. Therapeutic Protein C Activator for Myocardial Ischemia

    Amount: $1,913,015.00

    DESCRIPTION provided by applicant Rapidly progressing occlusion of the coronary artery and the subsequent acute myocardial ischemia is the most prevalent primary cause of acute myocardial infarcti ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  7. Therapeutic Protein C Activator for Myocardial Ischemia

    Amount: $260,864.00

    DESCRIPTION (provided by applicant): Rapidly progressing occlusion of the coronary artery and the subsequent acute myocardial ischemia is the most prevalent primary cause of acute myocardial infarcti ...

    SBIRPhase I2013Department of Health and Human Services
  8. Therapeutic factor XI blockade for sepsis

    Amount: $2,957,729.00

    DESCRIPTION (provided by applicant): This SBIR Phase II grant will support the commercial development of an injectable biological product candidate, a unique proprietary recombinant humanized anti-fac ...

    SBIRPhase II2012Department of Health and Human Services
  9. Factor XI inhibitor for thrombosis

    Amount: $2,510,043.00

    DESCRIPTION (provided by applicant): Thrombotic cardiovascular diseases including venous thromboembolism (VTE), deep vein thrombosis (DVT), myocardial infarction, and ischemic stroke, remain leading c ...

    SBIRPhase II2012Department of Health and Human Services
  10. Factor XI Inhibition for the Treatment of Ischemic Stroke

    Amount: $315,665.00

    DESCRIPTION (provided by applicant): One of the underlying causes of acute ischemic stroke (AIS) is the thrombotic-thromboembolic occlusion of cerebral blood vessels. Early use of tissue-type plasmino ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government